Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: A case-control study

T. A. Manuck, W. S. Watkins, M. S. Esplin, J. Biggio, R. Bukowski, S. Parry, H. Zhan, H. Huang, W. Andrews, George Saade, Y. Sadovsky, U. M. Reddy, J. Ilekis, M. Yandell, M. W. Varner, L. B. Jorde

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To compare maternal genotypes between women with and without significant prolongation of pregnancy in the setting of 17-alpha hydroxyprogesterone caproate (17-P) administration for the prevention of recurrent preterm birth (PTB). Design: Case-control. Setting: Three tertiary-care centres across the USA. Population: Women (n = 99) with ≥ 1 prior singleton spontaneous PTB, receiving 17-P. Methods: Women were classified as having successful prolongation of pregnancy during the 17-P treated pregnancy, in two ways: (1) Definition A: success/non-success based on difference in gestational age at delivery between 17-P-treated and untreated pregnancies (success: delivered ≥ 3 weeks later with 17-P) and (2) Definition B: success/non-success based on reaching term (success: delivered at term with 17-P). Main outcome measures: To assess genetic variation, all women underwent whole exome sequencing. Between-group sequence variation was analysed with the Variant Annotation, Analysis, and Search Tool (VAAST). Genes scored by VAAST with P < 0.05 were then analysed with two online tools: (1) Protein ANalysis THrough Evolutionary Relationships (PANTHER) and (2) Database for Annotation, Visualization, and Integrated Discovery (DAVID). Results: Using Definition A, there were 70 women with successful prolongation and 29 without; 1375 genes scored by VAAST had P < 0.05. Using Definition B, 47 women had successful prolongation and 52 did not; 1039 genes scored by VAAST had P < 0.05. PANTHER revealed key differences in gene ontology pathways. Many genes from definition A were classified as prematurity genes (P = 0.026), and those from definition B as pharmacogenetic genes (P = 0.0018); (P, non-significant after Bonferroni correction). Conclusion: A novel analytic approach revealed several genetic differences among women delivering early vs later with 17-P. Tweetable abstract: Several key genetic differences are present in women with recurrent preterm birth despite 17-P treatment.

Original languageEnglish (US)
JournalBJOG: An International Journal of Obstetrics and Gynaecology
DOIs
StateAccepted/In press - 2017

Fingerprint

Pharmacogenetics
Premature Birth
Case-Control Studies
Genes
Pregnancy
Exome
Gene Ontology
17-alpha-hydroxy-progesterone caproate
Tertiary Care Centers
Gestational Age
Proteins
Genotype
Mothers
Outcome Assessment (Health Care)
Databases
Population

Keywords

  • 17-Alpha hydroxyprogesterone caproate
  • Current preterm birth
  • Pharmacogenomics
  • Spontaneous prematurity

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth : A case-control study. / Manuck, T. A.; Watkins, W. S.; Esplin, M. S.; Biggio, J.; Bukowski, R.; Parry, S.; Zhan, H.; Huang, H.; Andrews, W.; Saade, George; Sadovsky, Y.; Reddy, U. M.; Ilekis, J.; Yandell, M.; Varner, M. W.; Jorde, L. B.

In: BJOG: An International Journal of Obstetrics and Gynaecology, 2017.

Research output: Contribution to journalArticle

Manuck, TA, Watkins, WS, Esplin, MS, Biggio, J, Bukowski, R, Parry, S, Zhan, H, Huang, H, Andrews, W, Saade, G, Sadovsky, Y, Reddy, UM, Ilekis, J, Yandell, M, Varner, MW & Jorde, LB 2017, 'Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: A case-control study', BJOG: An International Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/1471-0528.14485
Manuck, T. A. ; Watkins, W. S. ; Esplin, M. S. ; Biggio, J. ; Bukowski, R. ; Parry, S. ; Zhan, H. ; Huang, H. ; Andrews, W. ; Saade, George ; Sadovsky, Y. ; Reddy, U. M. ; Ilekis, J. ; Yandell, M. ; Varner, M. W. ; Jorde, L. B. / Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth : A case-control study. In: BJOG: An International Journal of Obstetrics and Gynaecology. 2017.
@article{bc29b68886f54084934f8ee2e639d474,
title = "Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: A case-control study",
abstract = "Objective: To compare maternal genotypes between women with and without significant prolongation of pregnancy in the setting of 17-alpha hydroxyprogesterone caproate (17-P) administration for the prevention of recurrent preterm birth (PTB). Design: Case-control. Setting: Three tertiary-care centres across the USA. Population: Women (n = 99) with ≥ 1 prior singleton spontaneous PTB, receiving 17-P. Methods: Women were classified as having successful prolongation of pregnancy during the 17-P treated pregnancy, in two ways: (1) Definition A: success/non-success based on difference in gestational age at delivery between 17-P-treated and untreated pregnancies (success: delivered ≥ 3 weeks later with 17-P) and (2) Definition B: success/non-success based on reaching term (success: delivered at term with 17-P). Main outcome measures: To assess genetic variation, all women underwent whole exome sequencing. Between-group sequence variation was analysed with the Variant Annotation, Analysis, and Search Tool (VAAST). Genes scored by VAAST with P < 0.05 were then analysed with two online tools: (1) Protein ANalysis THrough Evolutionary Relationships (PANTHER) and (2) Database for Annotation, Visualization, and Integrated Discovery (DAVID). Results: Using Definition A, there were 70 women with successful prolongation and 29 without; 1375 genes scored by VAAST had P < 0.05. Using Definition B, 47 women had successful prolongation and 52 did not; 1039 genes scored by VAAST had P < 0.05. PANTHER revealed key differences in gene ontology pathways. Many genes from definition A were classified as prematurity genes (P = 0.026), and those from definition B as pharmacogenetic genes (P = 0.0018); (P, non-significant after Bonferroni correction). Conclusion: A novel analytic approach revealed several genetic differences among women delivering early vs later with 17-P. Tweetable abstract: Several key genetic differences are present in women with recurrent preterm birth despite 17-P treatment.",
keywords = "17-Alpha hydroxyprogesterone caproate, Current preterm birth, Pharmacogenomics, Spontaneous prematurity",
author = "Manuck, {T. A.} and Watkins, {W. S.} and Esplin, {M. S.} and J. Biggio and R. Bukowski and S. Parry and H. Zhan and H. Huang and W. Andrews and George Saade and Y. Sadovsky and Reddy, {U. M.} and J. Ilekis and M. Yandell and Varner, {M. W.} and Jorde, {L. B.}",
year = "2017",
doi = "10.1111/1471-0528.14485",
language = "English (US)",
journal = "BJOG: An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth

T2 - A case-control study

AU - Manuck, T. A.

AU - Watkins, W. S.

AU - Esplin, M. S.

AU - Biggio, J.

AU - Bukowski, R.

AU - Parry, S.

AU - Zhan, H.

AU - Huang, H.

AU - Andrews, W.

AU - Saade, George

AU - Sadovsky, Y.

AU - Reddy, U. M.

AU - Ilekis, J.

AU - Yandell, M.

AU - Varner, M. W.

AU - Jorde, L. B.

PY - 2017

Y1 - 2017

N2 - Objective: To compare maternal genotypes between women with and without significant prolongation of pregnancy in the setting of 17-alpha hydroxyprogesterone caproate (17-P) administration for the prevention of recurrent preterm birth (PTB). Design: Case-control. Setting: Three tertiary-care centres across the USA. Population: Women (n = 99) with ≥ 1 prior singleton spontaneous PTB, receiving 17-P. Methods: Women were classified as having successful prolongation of pregnancy during the 17-P treated pregnancy, in two ways: (1) Definition A: success/non-success based on difference in gestational age at delivery between 17-P-treated and untreated pregnancies (success: delivered ≥ 3 weeks later with 17-P) and (2) Definition B: success/non-success based on reaching term (success: delivered at term with 17-P). Main outcome measures: To assess genetic variation, all women underwent whole exome sequencing. Between-group sequence variation was analysed with the Variant Annotation, Analysis, and Search Tool (VAAST). Genes scored by VAAST with P < 0.05 were then analysed with two online tools: (1) Protein ANalysis THrough Evolutionary Relationships (PANTHER) and (2) Database for Annotation, Visualization, and Integrated Discovery (DAVID). Results: Using Definition A, there were 70 women with successful prolongation and 29 without; 1375 genes scored by VAAST had P < 0.05. Using Definition B, 47 women had successful prolongation and 52 did not; 1039 genes scored by VAAST had P < 0.05. PANTHER revealed key differences in gene ontology pathways. Many genes from definition A were classified as prematurity genes (P = 0.026), and those from definition B as pharmacogenetic genes (P = 0.0018); (P, non-significant after Bonferroni correction). Conclusion: A novel analytic approach revealed several genetic differences among women delivering early vs later with 17-P. Tweetable abstract: Several key genetic differences are present in women with recurrent preterm birth despite 17-P treatment.

AB - Objective: To compare maternal genotypes between women with and without significant prolongation of pregnancy in the setting of 17-alpha hydroxyprogesterone caproate (17-P) administration for the prevention of recurrent preterm birth (PTB). Design: Case-control. Setting: Three tertiary-care centres across the USA. Population: Women (n = 99) with ≥ 1 prior singleton spontaneous PTB, receiving 17-P. Methods: Women were classified as having successful prolongation of pregnancy during the 17-P treated pregnancy, in two ways: (1) Definition A: success/non-success based on difference in gestational age at delivery between 17-P-treated and untreated pregnancies (success: delivered ≥ 3 weeks later with 17-P) and (2) Definition B: success/non-success based on reaching term (success: delivered at term with 17-P). Main outcome measures: To assess genetic variation, all women underwent whole exome sequencing. Between-group sequence variation was analysed with the Variant Annotation, Analysis, and Search Tool (VAAST). Genes scored by VAAST with P < 0.05 were then analysed with two online tools: (1) Protein ANalysis THrough Evolutionary Relationships (PANTHER) and (2) Database for Annotation, Visualization, and Integrated Discovery (DAVID). Results: Using Definition A, there were 70 women with successful prolongation and 29 without; 1375 genes scored by VAAST had P < 0.05. Using Definition B, 47 women had successful prolongation and 52 did not; 1039 genes scored by VAAST had P < 0.05. PANTHER revealed key differences in gene ontology pathways. Many genes from definition A were classified as prematurity genes (P = 0.026), and those from definition B as pharmacogenetic genes (P = 0.0018); (P, non-significant after Bonferroni correction). Conclusion: A novel analytic approach revealed several genetic differences among women delivering early vs later with 17-P. Tweetable abstract: Several key genetic differences are present in women with recurrent preterm birth despite 17-P treatment.

KW - 17-Alpha hydroxyprogesterone caproate

KW - Current preterm birth

KW - Pharmacogenomics

KW - Spontaneous prematurity

UR - http://www.scopus.com/inward/record.url?scp=85011281178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011281178&partnerID=8YFLogxK

U2 - 10.1111/1471-0528.14485

DO - 10.1111/1471-0528.14485

M3 - Article

C2 - 28139890

AN - SCOPUS:85011281178

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

ER -